- Home
- MITQ vs RNAZ Comparison
MITQ vs RNAZ Comparison
Compare MITQ & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- RNAZ
- Stock Information
- Founded
- MITQ N/A
- RNAZ 2016
- Country
- MITQ United States
- RNAZ United States
- Employees
- MITQ N/A
- RNAZ N/A
- Industry
- MITQ Telecommunications Equipment
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- MITQ Telecommunications
- RNAZ Health Care
- Exchange
- MITQ Nasdaq
- RNAZ Nasdaq
- Market Cap
- MITQ 7.6M
- RNAZ 6.1M
- IPO Year
- MITQ 2021
- RNAZ 2021
- Fundamental
- Price
- MITQ $0.75
- RNAZ $11.74
- Analyst Decision
- MITQ
- RNAZ Strong Buy
- Analyst Count
- MITQ 0
- RNAZ 1
- Target Price
- MITQ N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- MITQ 102.6K
- RNAZ 239.7K
- Earning Date
- MITQ 09-25-2025
- RNAZ 08-13-2025
- Dividend Yield
- MITQ N/A
- RNAZ N/A
- EPS Growth
- MITQ N/A
- RNAZ N/A
- EPS
- MITQ N/A
- RNAZ N/A
- Revenue
- MITQ $18,613,000.00
- RNAZ N/A
- Revenue This Year
- MITQ N/A
- RNAZ N/A
- Revenue Next Year
- MITQ N/A
- RNAZ N/A
- P/E Ratio
- MITQ N/A
- RNAZ N/A
- Revenue Growth
- MITQ N/A
- RNAZ N/A
- 52 Week Low
- MITQ $0.50
- RNAZ $6.15
- 52 Week High
- MITQ $1.55
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- MITQ 58.78
- RNAZ 67.96
- Support Level
- MITQ $0.74
- RNAZ $9.02
- Resistance Level
- MITQ $0.76
- RNAZ $17.24
- Average True Range (ATR)
- MITQ 0.05
- RNAZ 1.28
- MACD
- MITQ 0.00
- RNAZ 0.31
- Stochastic Oscillator
- MITQ 68.80
- RNAZ 40.21
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.